Researchers discover new markers for breast cancer that may aid diagnoses, point to new therapies

July 8, 2014 by Tiffany L Trent
Fluorescence micrograph of breast cancer cells. Credit: Lutz Langbein, Deutsches Krebsforschungszentrum

(Medical Xpress)—The fight against breast cancer is never-ending, but Virginia Tech researchers in the Medical Informatics and Systems Division at the Virginia Bioinformatics Institute have found additional diagnostic markers that may aid clinicians to better forecast and prevent the disease.

Since one in eight women are likely to develop in their lifetimes, finding better predictive markers is more important than ever.

The study was published in Breast Cancer Research and Treatment.

By using breast cancer germline (blood) samples from The Cancer Genome Atlas Project and comparing them with samples from cancer-free individuals whose genomes are found in the 1000 Genomes Project, the researchers pinpointed several novel markers that may not only reveal risks for breast cancer, but may yield therapeutic benefits, as well.

The research team specifically looked at microsatellite variation, which can be a predictor of cancer. Microsatellites are small regions of repeating DNA in the genome that can affect proper cellular function in a variety of ways.

"There is still a lot we can learn from looking at the human genome and how it can be affected in ways that may be associated with disease," said Natalie Fonville, a geneticist on the research team."This study is the first of many in which we are engaged that identify subtle genomic changes which together may add up to ."

Often referred to as "junk DNA" in the past, microsatellites are currently thought to be important in a number of diseases and genetic mutations.

Generally, mutations that occur are cleaned up by DNA repair mechanisms during replication, but not all of them are. Some of these mutations may lead to cancer.

Next-generation sequencing technology and new analytic tools now allow scientists to probe more deeply into the dark matter of DNA. This could yield markers that are much more reliable than those used at present, as well as possible genetic therapies in the future.

The technology described in the study has been licensed by Virginia Tech Intellectual Properties to Genomeon LLC.

"The use of microsatellite variations as diagnostics has the potential to transform the way cancer and other heritable diseases are diagnosed and treated," Michael B. Waitzkin, Genomeon's chief executive officer. This technology is a very exciting example of the possibilities for translating academic discoveries into clinical use," he observed.

Explore further: Aging contributes to rapid rates of genomic change, signaling challenges for personalized medicine

More information: "Microsatellite genotyping reveals a signature in breast cancer exomes." L. J. McIver, N. C. Fonville, E. Karunasena, and H. R. Garner. Breast Cancer Res Treat. 2014; 145: 791–798. Published online May 17, 2014. doi:  10.1007/s10549-014-2908-8

Related Stories

Aging contributes to rapid rates of genomic change, signaling challenges for personalized medicine

June 24, 2014
(Medical Xpress)—Exploiting individual genomes for personalized medicine may be more complicated than medical scientists have suspected, researchers at Virginia Bioinformatics Institute have discovered.

New test predicts the risk of non-hereditary breast cancer

June 27, 2014
A simple blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, even in the absence of a high-risk BRCA1 gene mutation, according to research published in the open ...

Faster genetic testing method will likely transform care for patients with breast cancer

March 27, 2014
Faster and cheaper DNA sequencing techniques will likely improve care for patients with breast cancer but also create challenges for clinicians as they counsel patients on their treatment options. Those are among the conclusions ...

Breast cancer prognosis associated with oncometabolite accumulation

December 9, 2013
The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the National ...

Four new genes confirmed to increase familial breast cancer risk

June 4, 2014
Four new genes have been added to the growing list of those known to cause increased breast cancer risk when mutated through the efforts of researchers at Huntsman Cancer Institute (HCI) at the University of Utah, who lead ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.